AVITA Medical, Inc. updated revenue guidance for the year 2023. As a result of these dynamics, the Company is revising its expected full year 2023 commercial revenue from the previously disclosed range of $51 million to $53 million to a range of approximately $49.5 million to $50.5 million, with lower and upper bounds reflecting growth rates of approximately 45% and 48%, respectively, over the same period in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.26 USD | -5.17% | -5.60% | -39.80% |
04-17 | Wilsons Downgrades Avita Medical to Market-Weight From Overweight; Price Target is AU$3.03 | MT |
04-11 | BTIG Research Downgrades Avita Medical to Neutral From Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.80% | 213M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- RCEL Stock
- News AVITA Medical, Inc.
- AVITA Medical, Inc. Updates Revenue Guidance for the Year 2023